12 / 48
Reck M, et al. IMpower150 PFS analysis.
0,25
IMPOWER 150: PFS in key biomarker
populations
Population
n (%)
a
ITT (including
EGFR
/
ALK
mutant +) 800 (100%)
EGFR
/
ALK
mutant + only
b
108 (14%)
ITT-WT
692 (87%)
Teff-high (WT)
284 (43%)
Teff-low (WT)
374 (57%)
PD-L1 IHC TC2/3 or IC2/3 (WT)
244 (35%)
PD-L1 IHC TC1/2/3 or IC1/2/3 (WT) 354 (51%)
PD-L1 IHC TC0 and IC0 (WT)
338 (49%)
PD-L1 IHC TC3 or IC3 (WT)
135 (20%)
PD-L1 IHC TC0/1/2 or IC0/1/2 (WT)
557 (80%)
Median PFS, mo
1.0
In favour of Arm C:
bev + CP
Hazard Ratio
c
In favour of Arm B:
atezo + bev + CP
0.61
0.59
0.76
0.48
0.50
0.77
0.51
0.62
1.25
0.39
0.68
Arm
B
Arm
C
8.3 6.8
9.7 6.1
8.3 6.8
11.3 6.8
7.3 7.0
11.1 6.8
11.0 6.8
7.1 6.9
12.6 6.8
8.0 6.8